Nucleosome Assembly Alters the Accessibility of the Antitumor Agent Duocarmycin B2 to Duplex DNA

Area of Science:

• Biochemistry
• Molecular Biology
• Drug Discovery

Background:

• Nucleosomes are fundamental DNA packaging units in eukaryotes.
• Antitumor agents often target DNA, but their efficacy can be modulated by DNA accessibility.
• Understanding drug-target interactions within chromatin is crucial for developing effective cancer therapies.

Purpose of the Study:

• To investigate the reactivity of the antitumor agent duocarmycin B2.
• To assess how nucleosome architecture influences duocarmycin B2's DNA alkylation efficiency.
• To compare drug reactivity on core DNA, linker DNA, and naked DNA.

Main Methods:

• In vitro studies were performed to evaluate drug-DNA interactions.
• Sequencing gel electrophoresis was utilized to quantify alkylation levels.
• Duocarmycin B2's reactivity was assessed on reconstituted nucleosomes and naked DNA.

Main Results:

• Alkylation efficiencies of duocarmycin B2 were significantly decreased on core DNA compared to naked DNA.
• Reactivity of duocarmycin B2 increased at histone-free linker DNA sites.
• Nucleosome assembly demonstrably alters the accessibility of duplex DNA to duocarmycin B2.

Conclusions:

• Nucleosome structure plays a critical role in modulating the accessibility and reactivity of antitumor agents like duocarmycin B2.
• The differential reactivity observed suggests that targeting linker DNA regions within nucleosomes may be a viable strategy.
• These findings could inform the rational design of novel antitumor agents with improved efficacy by considering chromatin architecture.